types of diseases
Item
1. documentation of disease. patients must have one of the following disease types:
boolean
C0457464 (UMLS CUI [1])
Diffuse Large B-Cell Lymphoma | Mediastinal (Thymic) Large B-Cell Lymphoma | Peripheral T-Cell Lymphoma
Item
diffuse large cell non-hodgkin's lymphoma, mediastinal b-cell lymphoma, or peripheral t-cell lymphoma that is:
boolean
C0079744 (UMLS CUI [1])
C1292754 (UMLS CUI [2])
C0079774 (UMLS CUI [3])
Primary Refractory | Complete response Less Than
Item
primary refractory (achievement less than complete response)
boolean
C2347678 (UMLS CUI [1])
C0677874 (UMLS CUI [2,1])
C0439092 (UMLS CUI [2,2])
Salvage Therapy Quantity Recurrent disease | Salvage Therapy Quantity Refractory | Partial response Less Than
Item
relapsed and refractory (achievement less than a partial response) to at least a single salvage therapy
boolean
C0085405 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C0085405 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C1521726 (UMLS CUI [3,1])
C0439092 (UMLS CUI [3,2])
Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma Primary | Follicular Lymphoma International Prognostic Index High
Item
relapsed or primary refractory follicular lymphoma (fl) with a high fl international prognostic index.
boolean
C1335701 (UMLS CUI [1])
C1335723 (UMLS CUI [2,1])
C0205225 (UMLS CUI [2,2])
C4040298 (UMLS CUI [3,1])
C0205250 (UMLS CUI [3,2])
Indolent lymphoma | Lymphoma, Follicular | Marginal zone lymphoma | Lymphoma transformation | Large cell lymphoma
Item
large cell transformation of lymphoma from a more indolent lymphoma (e.g., follicular, marginal zone, etc.)
boolean
C1334170 (UMLS CUI [1])
C0024301 (UMLS CUI [2])
C0242647 (UMLS CUI [3])
C1536010 (UMLS CUI [4])
C0024302 (UMLS CUI [5])
Mantle cell lymphoma
Item
mantle cell lymphoma that is:
boolean
C0334634 (UMLS CUI [1])
Primary Refractory | Complete response Less Than
Item
primary refractory (achievement less than complete response)
boolean
C2347678 (UMLS CUI [1])
C0677874 (UMLS CUI [2,1])
C0439092 (UMLS CUI [2,2])
Recurrent disease | Chemosensitivity Independent of
Item
relapsed (regardless of chemosensitivity of relapsed disease)
boolean
C0277556 (UMLS CUI [1])
C2347610 (UMLS CUI [2,1])
C0332291 (UMLS CUI [2,2])
Transplantation of autologous hematopoietic stem cell Exclusion
Item
2. patients who received prior autologous stem cell transplantation are not eligible.
boolean
C1831743 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
Age
Item
3. patient age 18-70 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
4. performance status ecog 0-1
boolean
C1520224 (UMLS CUI [1])
Laboratory Results Patient need for
Item
5. required baseline laboratory values:
boolean
C1254595 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
Left ventricular ejection fraction Corrected
Item
lvef > 45% corrected
boolean
C0428772 (UMLS CUI [1,1])
C0205202 (UMLS CUI [1,2])
Carbon Monoxide Diffusing Capability Test | Hemoglobin measurement Corrected
Item
dlco > 50% of predicted value (corrected for hemoglobin)
boolean
C1516251 (UMLS CUI [1])
C0518015 (UMLS CUI [2,1])
C0205202 (UMLS CUI [2,2])
Creatinine measurement, serum | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
serum creatinine ≤ 2.0 mg/dl or estimated creatinine clearance of ≥60 ml/min
boolean
C0201976 (UMLS CUI [1])
C2711451 (UMLS CUI [2])
Serum total bilirubin measurement
Item
bilirubin < 1 x upper limit of normal value.
boolean
C1278039 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
ast and alt < 1 x upper limit of normal value.
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
Informed Consent
Item
6. signed written informed consent. patient must be capable of understanding the investigational nature of the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
boolean
C0021430 (UMLS CUI [1])
Communicable Disease | Antibiotics Oral Patient need for | Antibiotics Intravenous Patient need for
Item
1. no active infection. patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.
boolean
C0009450 (UMLS CUI [1])
C0003232 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0686904 (UMLS CUI [2,3])
C0003232 (UMLS CUI [3,1])
C1522726 (UMLS CUI [3,2])
C0686904 (UMLS CUI [3,3])
HIV Infection | Immune System Disease High risk of Infection | Therapeutic immunosuppression intense Causing Infection
Item
2. no hiv disease. patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.
boolean
C0019693 (UMLS CUI [1])
C0021053 (UMLS CUI [2,1])
C0332167 (UMLS CUI [2,2])
C3714514 (UMLS CUI [2,3])
C0021079 (UMLS CUI [3,1])
C0522510 (UMLS CUI [3,2])
C0678227 (UMLS CUI [3,3])
C3714514 (UMLS CUI [3,4])
Pregnancy | Breast Feeding | Childbearing Potential Pregnancy test negative | Reproductive potential Contraceptive methods | Contraceptives, Oral | Hormonal contraception | CONTRACEPTION NORPLANT | Barrier Contraception Double | Vaginal contraceptive diaphragm | Condom
Item
3. non-pregnant and non-nursing. treatment under this protocol would expose a fetus to significant risks. women of childbearing potential should have a negative pregnancy test prior to study entry. women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (norplant®), or double barrier method (diaphragm plus condom).
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0427780 (UMLS CUI [3,2])
C4034483 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0009905 (UMLS CUI [5])
C2985296 (UMLS CUI [6])
C0742782 (UMLS CUI [7])
C0004764 (UMLS CUI [8,1])
C0205173 (UMLS CUI [8,2])
C0042241 (UMLS CUI [9])
C0677582 (UMLS CUI [10])